Key result
Lower baseline PACS is linked to developing atrial fibrillation, which affects ~16% of ibrutinib patients.
Why the study?
Ibrutinib increases the risk of atrial fibrillation in chronic lymphocytic leukemia, but early identification of susceptible patients remains a major challenge in cardio-oncology.
Does baseline transthoracic echocardiography with left atrial strain imaging predict the development of atrial fibrillation in patients with chronic lymphocytic leukemia receiving ibrutinib?
Prospective pilot study (n=45)
No
Does baseline transthoracic echocardiography with left atrial strain imaging predict the development of atrial fibrillation in patients with chronic lymphocytic leukemia receiving ibrutinib?
Baseline impairment of left atrial contractile function (measured by Peak Atrial Contraction Strain) may serve as an echocardiographic marker to identify patients at high risk for ibrutinib-related atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Baseline PACS may identify ibrutinib-related AF risk; hypothesis-generating and requires validation before clinical use.
Background: Bruton’s tyrosine kinase inhibitors, particularly ibrutinib, have improved outcomes in patients with chronic lymphocytic leukemia but are associated with an increased risk of atrial fibrillation. The early identification of patients with increased susceptibility to atrial fibrillation remains a major challenge in cardio-oncology. Methods: This prospective pilot study included 45 patients with chronic lymphocytic leukemia treated with ibrutinib. All patients underwent comprehensive transthoracic echocardiography at baseline and after 6 months. Left atrial structure and function were assessed, with particular emphasis on speckle-tracking-derived left atrial strain parameters, including peak atrial longitudinal strain and peak atrial contraction strain. Results: At follow-up, a modest but significant increase in indexed left atrial volume was observed, while left atrial functional parameters remained stable. Patients who developed atrial fibrillation showed significantly lower baseline Peak Atrial Contraction Strain values compared with those who remained in sinus rhythm, whereas no significant differences in Peak Atrial Longitudinal Strain were detected. Conclusions: Ibrutinib-related atrial fibrillation appears to be driven primarily by pre-existing atrial vulnerability rather than early drug-induced atrial dysfunction. The baseline impairment of left atrial contractile function may represent a candidate echocardiographic marker of atrial functional vulnerability and may inform cardiovascular surveillance and monitoring strategies in patients treated with ibrutinib.
No takes yet. Share an insight, caveat, or question.
Gammaldi et al. (2026) conducted a prospective pilot study in Patients with chronic lymphocytic leukemia receiving ibrutinib therapy (n=45). Ibrutinib vs. No comparator was evaluated on Occurrence of ibrutinib-related atrial fibrillation (IRAF) during 6-month follow-up. Ibrutinib therapy was associated with 15.6% incidence of atrial fibrillation and patients developing AF had lower baseline peak atrial contraction strain.
Synapse has enriched 10 related papers. Consider them for comparative context: